title: New drugs for pediatric epilepsy.
abstract: The last 2 decades have witnessed an unprecedented period of new antiepileptic drug (AED) development. Newer-generation AEDs have been developed with the intention of improving the ease of use, decreasing drug interactions, decreasing adverse side effects, and identifying drugs with unique mechanisms of action, some of which may bear relevance to potential neuroprotective activity. Drug trials have also been refined in some cases to evaluate AED efficacy in children and against distinct epilepsy syndromes. This progress provides many new treatment options for the child neurologist facing children with epilepsy but also introduces the burden of determining appropriate AED choices. Here we highlight 6 new antiepileptic medications recently approved or pending approval for use in the United States: lacosamide, rufinamide, vigabatrin, retigabine, brivaracetam, and clobazam. For each of these medications, we present information regarding the history of drug development, proposed mechanism(s) of action, pharmacokinetics and recommended dosing, evidence for clinical efficacy, tolerability, and when, available, any unique features that are relevant for the pediatric population.
authors.affiliation: Pediatric Epilepsy Program, Department of Neurology, Massachusetts General Hospital, Boston, MA, USA.
authors.forename: Catherine J
authors.initials: CJ
authors.lastname: Chu-Shore
authors.forename: Elizabeth A
authors.initials: EA
authors.lastname: Thiele
mesh_terms: D000367:Age Factors; D000927:Anticonvulsants / Q000009:adverse effects / Q000494:pharmacology / Q000627:therapeutic use*; D002648:Child; D002675:Child, Preschool; D015507:Drugs, Investigational / Q000009:adverse effects / Q000494:pharmacology / Q000627:therapeutic use*; D004827:Epilepsy / Q000188:drug therapy*; D006801:Humans
chemical_list: D000927:Anticonvulsants; D015507:Drugs, Investigational